B-intervention	0	7	Topical
I-intervention	8	20	atorvastatin
O	21	22	1
O	22	23	%
O	24	27	for
O	28	38	prevention
O	39	41	of
B-condition	42	46	skin
I-condition	47	55	toxicity
O	56	58	in
B-eligibility	59	67	patients
I-eligibility	68	77	receiving
I-eligibility	78	87	radiation
I-eligibility	88	95	therapy
I-eligibility	96	99	for
I-eligibility	100	106	breast
I-eligibility	107	113	cancer
O	113	114	:
O	115	116	a
O	117	127	randomized
O	127	128	,
O	129	135	double
O	135	136	-
O	136	141	blind
O	141	142	,
O	143	150	placebo
O	150	151	-
O	151	161	controlled
O	162	167	trial
O	167	168	.

O	169	172	The
O	173	180	purpose
O	181	183	of
O	184	188	this
O	189	199	randomized
O	199	200	,
O	201	208	placebo
O	208	209	-
O	209	219	controlled
O	219	220	,
O	221	227	double
O	227	228	-
O	228	233	blind
O	234	239	study
O	240	243	was
O	244	246	to
O	247	258	investigate
O	259	262	the
O	263	273	preventive
O	274	280	effect
O	281	283	of
O	284	291	topical
O	292	306	administration
O	307	309	of
O	310	322	atorvastatin
O	323	324	(
O	324	327	ATV
O	327	328	)
O	329	331	on
O	332	335	the
O	336	341	acute
O	342	351	radiation
O	351	352	-
O	352	359	induced
O	360	364	skin
O	365	373	toxicity
O	374	376	in
O	377	385	patients
O	386	390	with
O	391	397	breast
O	398	404	cancer
O	404	405	.

B-total-participants	406	413	Seventy
O	414	420	breast
O	421	427	cancer
O	428	436	patients
O	437	441	were
O	442	450	randomly
O	451	459	assigned
O	460	462	to
O	463	466	use
O	467	474	topical
O	475	478	ATV
O	479	480	1
O	480	481	%
O	482	484	or
B-control	485	492	placebo
I-control	493	497	gels
O	498	504	during
O	505	517	radiotherapy
O	518	523	twice
O	524	529	daily
O	529	530	.

O	531	540	Radiation
O	540	541	-
O	541	548	induced
O	549	559	dermatitis
O	560	563	was
O	564	574	classified
O	575	584	according
O	585	587	to
O	588	591	the
O	592	601	radiation
O	602	609	therapy
O	610	618	oncology
O	619	624	group
O	625	626	(
O	626	630	RTOG
O	630	631	)
O	632	640	criteria
O	640	641	,
O	642	644	as
O	645	649	well
O	650	652	as
O	653	657	pain
O	658	661	and
O	662	669	itching
O	670	674	were
O	675	681	scored
O	682	691	according
O	692	694	to
O	695	698	VAS
O	699	700	(
O	700	706	visual
O	707	715	analogue
O	716	721	scale
O	721	722	)
O	723	726	for
O	727	728	6
O	728	729	Ã‚
O	730	735	weeks
O	736	738	of
O	739	748	treatment
O	748	749	.

O	750	757	Topical
O	758	772	administration
O	773	775	of
O	776	779	ATV
O	780	783	gel
O	784	790	during
O	791	803	radiotherapy
O	804	811	reduced
O	812	825	significantly
B-outcome	826	835	radiation
I-outcome	835	836	-
I-outcome	836	843	induced
I-outcome	844	850	breast
I-outcome	851	859	swelling
I-outcome	859	860	,
I-outcome	861	868	itching
I-outcome	868	869	,
I-outcome	870	873	and
I-outcome	874	878	pain
O	879	881	in
O	882	888	breast
O	889	895	cancer
O	896	904	patients
O	905	907	by
O	908	915	factors
O	916	918	of
O	919	920	1
O	920	921	.
O	921	922	8
O	922	923	,
O	924	925	1
O	925	926	.
O	926	927	7
O	927	928	,
O	929	932	and
O	933	934	1
O	934	935	.
O	935	936	5
O	936	937	,
O	938	950	respectively
O	950	951	.

O	952	955	ATV
O	956	963	reduced
O	964	967	the
B-outcome	968	975	redness
I-outcome	976	982	caused
I-outcome	983	985	by
I-outcome	986	998	radiotherapy
O	999	1001	in
O	1002	1010	patients
O	1011	1013	as
O	1014	1022	compared
O	1023	1027	with
O	1028	1035	placebo
O	1035	1036	;
O	1037	1044	however
O	1044	1045	,
O	1046	1050	this
O	1051	1061	difference
O	1062	1065	was
O	1066	1079	statistically
O	1080	1083	not
O	1084	1095	significant
O	1095	1096	.

O	1097	1100	ATV
O	1101	1104	was
O	1105	1109	able
O	1110	1112	to
O	1113	1119	reduce
O	1120	1133	significantly
B-outcome	1134	1141	itching
I-outcome	1141	1142	,
I-outcome	1143	1149	breast
I-outcome	1150	1155	edema
I-outcome	1155	1156	,
I-outcome	1157	1160	and
I-outcome	1161	1165	pain
O	1166	1168	in
O	1169	1177	patients
O	1178	1184	during
O	1185	1197	radiotherapy
O	1197	1198	.
